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Critically ill children in pediatric intensive care units are commonly indicated for blood 
transfusion due to many reasons. Children are quite different from adults during 
growth and development, and that should be taken into consideration. It is very dif-
ficult to establish a universal transfusion guideline for critically ill children, especially 
preterm neonates. Treating underlying disease and targeted replacement therapy are 
the most effective approaches. Red blood cells are the first choice for replacement 
therapy in decompensated anemic patients. The critical hemoglobin concentration 
may be higher in critically ill children for many reasons. Whole blood is used only in the 
following conditions or diseases: (1) exchange transfusion; (2) after cardiopulmonary 
bypass; (3) extracorporeal membrane oxygenation; (4) massive transfusion, especially 
in multiple component deficiency. The characteristics of hemorrhagic diseases are 
so varied that their therapy should depend on the specific needs associated with the 
underlying disease. In general, platelet transfusion is not needed when a patient has 
platelet count greater than 10,000/mm3 and is without active bleeding, platelet func-
tional deficiency or other risk factors such as sepsis. Patients with risk factors or 
age less than 4 months should be taken into special consideration, and the critical 
thrombocyte level will be raised. Platelet transfusion is not recommended in patients 
with immune-mediated thrombocytopenia or thrombocytopenia due to acceleration 
of platelet destruction without active bleeding or life-threatening hemorrhage. There 
are many kinds of plasma-derived products, and recombinant factors are commonly 
used for hemorrhagic patients due to coagulation factor deficiency depending on 
the characteristics of the diseases. The most effective way to correct disseminated 
intravascular coagulation (DIC) is to treat the underlying disease. Anticoagulant ther-
apy is very important; heparin is the most common agent used for DIC but the results 
are usually not satisfactory. Antithrombin III, protein C, or recombinant thrombomodu-
lin has been used successfully to treat this condition. For reducing the risk of organism 
transmission and adverse reactions resulting from blood transfusion, the following 
measures have been suggested: (1) replacement therapy using products other than 
blood (e.g., erythropoietin, iron preparation, granulocyte colony-stimulating factor); 
(2) special component replacement therapy for specific diseases; (3) autotransfusion; 
(4) subdividing whole packed blood products into smaller volumes to reduce donor 
exposure; (5) advances in virus-inactivating procedures. To avoid viral transmission, 
vapor-heated or pasteurized products and genetic recombinant products are recom-
mended. Cytomegalovirus (CMV)-seronegative blood, leukoreduced and/or irradiated 
blood are recommended for prevention of CMV infection, graft-versus-host-disease 
and alloimmunization in neonate and immunocompromised patient transfusion. There is 
no reason to prescribe a plasma product for nutritional supplementation because of 
the risk of complications. The principle: complications of transfusion must be avoided, 
the rate of blood exposure should be reduced and the safety of the transfused 
agents or components should be maintained must always be kept in mind.
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1. Introduction
Critically ill children in the pediatric intensive care 
unit (PICU) may be commonly indicated for blood 
product transfusion for the following purposes: 
(1) maintenance of the hemoglobin (Hb) level and 
oxygen-carrying capacity; (2) restoration of blood 
volume and cardiovascular function; (3) for normal 
hemostatic function. Children are quite different 
from adults during growth and development, and 
that should be taken into different consideration.1−5 
Common diseases or conditions that may be indica-
tion for transfusion therapy are shown in Table 1.5 
Blood component transfusion is a very effective but 
dangerous way to achieve the purposes mentioned 
above. Serious complications resulting from trans-
fusion may be encountered, and the safety of blood 
products has become a very important issue, espe-
cially in the neonatal field and certain immuno-
compromised states. To reduce the risk of organism 
transmission and the occurrence of adverse reac-
tions, the following measures have been suggested: 
(1) replacement therapy using products other than 
blood such as erythropoietin, iron preparation, gran-
ulocyte colony-stimulating factor (G-CSF) or normal 
saline; (2) special component replacement therapy 
for specific diseases; (3) autotransfusion; (4) subdi-
viding the whole packed blood products into smaller 
volumes to reduce donor exposure; (5) advances in 
viral-inactivating technology.1−12 The major blood 
products used for transfusion therapy and their char-
acteristics and indications are shown in Table 2.5,8 
The indication and treatment guidelines for red cell 
products as well as other components and their spe-
cial considerations in practice will be discussed in 
this paper in detail.
2.  Treatment for anemia or volume 
deficit patients
2.1.  General consideration in the transfusion 
of red blood cell products
Anemia, defined as Hb concentration below the 
age-matched normal range, occurred in 36.7% of 
critically ill children in a multidisciplinary PICU.2 
The anemia resulted in 15% of critically ill children 
receiving a transfusion during their PICU stay. The 
most important consequence related to anemia is 
the reduction in oxygen delivery. Anemia can de-
crease oxygen-carrying capacity significantly. The 
process adaptive to acute anemia include: (1) in-
creased extraction of available oxygen; (2) increased 
heart rate, stroke volume, and cardiac output; (3) 
a redistribution of blood flow from non-vital organs 
toward the heart and brain, at the expense of the 
splanchnic vascular bed; (4) a shift to the right of 
the oxyhemoglobin-dissociation curve; and (5) en-
hanced erythropoietin (EPO) production and release.2 
A number of diseases and hosts may impair these 
adaptive mechanisms, especially in critical ill chil-
dren. Red blood cells (RBC) are the first choice for 
replacement therapy in decompensated anemic pa-
tients. The cardiovascular physiology and its response 
to anemia and the disease process are different 
in children compared with adults. RBC transfusion 
should be given more stringently in children than 
adults because of the lower Hb level. In children 
without cardiopulmonary disease before surgery, 
maintaining Hb level higher than 8 g/dL may not be 
necessary because of their higher compensation abil-
ity.13 Factors other than Hb concentration that should 
be considered in deciding whether to transfuse RBCs 
Table 1  Common diseases with hematology/oncology problems needing transfusion in the PICU
Cancer: various, especially under chemotherapy or irradiation, e.g., leukemia, lymphoma etc.
Diseases due to thrombocyte dysfunction or deficiency, e.g., idiopathic thrombocytopenic purpura with active 
 bleeding, or for procedure, aplastic anemia, thrombasthenia, malignancies, etc.
Anemic diseases due to various underlying disorders
Congenital or acquired coagulopathies, e.g., hemophilia, liver failure, disseminated intravascular coagulation, etc.
Systemic infectious diseases with disseminated intravascular coagulation or hematological problems
Collagen diseases manifesting with thrombocytopenia and/or vasculitis, e.g., systemic lupus erythematosus, 
 juvenile rheumatoid arthritis/rheumatoid arthritis, etc.
Cardiovascular diseases under antithrombotic and/or anticoagulation therapy
Vasculitis due to various underlying diseases with hematological complications, e.g., in Henoch-Schonlein purpura, 
 systemic lupus erythematosus, etc.
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include: (1) the patient’s symptoms, signs, and func-
tional capacities; (2) the presence or absence of 
cardiorespiratory and central nervous diseases; (3) 
the cause and anticipated course of the disease; (4) 
alternative treatments such as recombinant EPO.13 
There is a great debate about what the lowest Hb 
level and critical oxygen delivery are under which 
oxygen consumption is in jeopardy. Optimal and safe 
lower limits of transfusion threshold have not been 
established for critically ill children and newborns/
infants. There is no consensus on the Hb concentra-
tion that should prompt a physician to prescribe RBC 
transfusion to critically ill patients. Unanimous guide-
lines for blood transfusion in critically ill children and 
premature infants are also not available. Suggested 
transfusion thresholds from major textbooks range 
from 4.0 to 16.0 g/dL for different underlying con-
ditions in critical ill children.2,3,5,7,13 Despite the 
limited clinical evidence, there are many guide-
lines that address transfusion practice in critically 
ill children. They are based largely upon expert opin-
ion, common practice, and evidence extrapolated 
from the adult literature, rather than high-quality 
clinical trials conducted in children. The general 
guidelines for pediatric RBC transfusion are shown 
in Table 3.1,2,5,13 The ultimate criterion establishing 
the need for transfusion is evidence of impaired tis-
sue oxygenation. The critical Hb concentration may 
be higher in critically ill children for many reasons, 
which include: (1) basic metabolic requirement is 
Table 2  Classification of RBC products* and their uses
Products Contents Volume Application
Packed RBC† RBC 100 mL 150 mL Anemia without volume deficit 
 Plasma 40 mL
 Stable factors 40 U
Leukoreduced RBC RBC 90 mL 120 mL Anemic patients allergic to leukocyte or
 WBC < 5 × 106   plasma protein; long-term
    transfused patients
Washed RBC RBC 90 mL 130 mL Anemic patients allergic to leukocyte or 
 WBC < 5 × 108   plasma protein 
 (leukocytes, no function)
Frozen RBC RBC 90 mL 130 mL Anemic patients allergic to leukocyte or 
    plasma protein; rare blood type
Whole blood† RBC 100 mL 285 mL Patients with RBC and volume deficit 
 Plasma 150 mL 
 Stable factors 120 U
Fresh blood† (storage < 3 d) RBC 100 mL 285 mL Newborn/infant/very sick patients with 
 Plasma 150 mL   RBC and volume deficit; BET 
 Stable factors 120 U
 Unstable factors 80 U
Stored frozen plasma,  Plasma 120 mL 120 mL Volume expander or stable factors 
 cryopreserved beyond Stable factors 90 U   (II, VII, IX, X) replacement
 8 hr after collection Factors V, VIII and 
  platelets deficit
Fresh frozen plasma,  Plasma 120 mL 135 mL Factor replacement
 cryopreserved within  All factors 90 U
 4 hr after collection Without platelets
Cryoprecipitates Fibrinogen 125 mg  20 mL Factors VIII, XIII and vWF replacement
 Factors VIII & XIII > 45 U    therapy
 Frinolectin & vWF 20−30 U
Platelet concentrates Platelets about 2−3 × 1010 35 mL Platelet deficiency or dysfunction
Granulocyte concentrates Granulocytes 1 × 109 25 mL Septic patients with neutropenia 
    unresponsive to antibiotic treatment
*Products from 250 mL whole blood (1 U in Taiwan); †leukocytes/platelets present but of no use for transfusion.
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higher; (2) stress experienced by critically ill chil-
dren and their diseases frequently increase oxygen 
consumption; (3) critical threshold is shifted to the 
right in critically ill children.2 In general, blood trans-
fusion within the first week of life is recommended 
when hematocrit is below 40% in infants with res-
piratory distress and below 30% in infants without 
respiratory distress. A suggested volume of trans-
fused blood of 10−15 mL/kg in 82.6% of PICU re-
sponders has been postulated by the European Study 
Group.3 For avoidance of overloading, unnecessary 
component exposure and their complications, whole 
blood is used only in the following conditions or 
diseases: (1) exchange transfusion; (2) after cardio-
pulmonary bypass; (3) extracorporeal membrane 
oxygenation; (4) massive transfusion, especially in 
multiple component deficiency.13
2.2.  Special consideration in neonatology 
and special conditions
Special consideration should always be given to 
neo nates, stem cell transplantation candidates and 
immunocompromised patients as transfusion may 
cause very serious complications. For example, 
graft-versus-host disease (GVHD) and transfusion-
transmitted infectious diseases such as cytomega-
lovirus (CMV) infection are very common in these 
patients.1,13 The condition of a neonate is vastly dif-
ferent from that of adults and older children. The 
characteristics of the neonate hematological system 
in transfusion therapy are listed in Table 4.1,14
The EPO response to decreased oxygen availa-
bility diminishes in preterm infants compared to 
anemic patients. The more immature the infant, 
the lower his EPO level and the response to anemia 
occurs. EPO therapy for these patients has been 
suggested.2,5,6,12 The increased incidence of retro-
lental fibroplasias and necrotizing enterocolitis in 
transfusion for neonates should be kept in mind in 
every transfusion procedure. Replacement of a large 
amount of blood by transfusion will lead to a right 
shift in the oxygen dissociation curve. This enhances 
oxygen delivery to the tissue and increases the risk 
of retrolental fibroplasias. Necrotizing enterocolitis 
is usually found after RBC transfusion in critically ill 
infants due to splanchnic vascular bed ischemia.2,15,16 
The more blood is transfused, the more complica-
tions occur. Efforts to avoid blood transfusion and 
to reduce the exposure to blood in critically ill chil-
dren by subdividing a whole pack of RBCs into halves 
or smaller volumes may be an effective measure to 
reduce donor exposure.2,17,18
Blood loss due to diagnostic sampling has been de-
scribed as the most common cause of anemia in hos-
pitalized infants and intensifies “non-physiological” 
anemia in the premature infant in whom 10 mL of 
blood may represent more than 10% of the total blood 
volume. In a 2-day period, 10−15% of the infant’s 
blood volume may be removed.10,11 Obladen et al 
mentioned the study results of Nexø et al (1981) 
that 1−13 samples were collected from each infant 
per day, and the average blood loss within 4 weeks 
was 7−51 mL/kg and 25% of the collected blood vol-
ume exceeded the amount necessary for the labo-
ratory.10 Twice as much blood was collected from 
critically ill patients than from “healthy” preterm 
infants.10 Madsen et al postulated that the mean 
blood loss and transfusion volume were 13.6 mL/kg 
and 6.3 mL/kg, respectively, in extremely low ges-
tational age and in critically ill infants during the 
first week.11 Everyone involved in ordering or collect-
ing blood from preterm infants should be aware of 
the fact that sampling is a painful and risky proce-
dure in neonatal practice. Blood testing should be 
restricted to the minimum required for proper clini-
cal management of the preterm infant. Leukoreduced 
and/or irradiated blood products are preferred for 
Table 3   Guideline for RBC transfusion in pediatric 
field
Children and adolescents
 Acute blood loss > 25% of circulating blood volume
 Hb < 8 g/dL in perioperative period
 Hb < 8 g/dL and symptomatic chronic disease
 Hb < 8 g/dL and marrow failure
 Hb < 13 g/dL and severe cardiopulmonary disease
Infants within first 4 months of life
 Hb < 8 g/dL and symptomatic anemia
 Hb < 10 g/dL and major surgery
 Hb < 10 g/dL and moderate pulmonary disease
 Hb < 13 g/dL and severe pulmonary disease
 Hb < 13 g/dL and severe cardiac disease
Table 4   Characteristics of hematological system in 
neonate
It is adapted to low intrauterine oxygen tension
Deficiency in hemostatic components and their 
 function
Antibodies identified in the newborn infant’s serum 
 are of maternal origin
Immunocompromised state
Serial blood sampling is usually a risk leading to anemia
More susceptible to citrate intoxication and heparin-
 induced hemorrhage
Efforts to reduce the number and volume of blood 
 transfusions and donor exposure should always be 
 kept in mind
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neonates/infants, especially preterms, transplanta-
tion candidates and immunocompromised patients 
for avoiding GVHD and viral infection.2,5,19,20
The choice of blood products for exchange 
transfusion (BET), red cell transfusion in neonates 
or infants less than 4 months of age and stem cell 
transplantation are very important issues. Blood for 
exchange transfusion should be as fresh as possi-
ble. When choosing blood products in BET for Rh-
incompatible hemolytic disease of the newborn, 
Rh-negative blood should be insisted on, and both 
the ABO blood type of the mother and compatibil-
ity with the mother’s serum should be taken into 
consideration (Table 5).8,19 The donor blood used in 
Rh-incompatibility obtained before delivery should 
be Rh-negative and O type with low anti-A and anti-B 
titer and compatible with the mother’s serum in in-
direct cross-matching test. After delivery, blood 
should be obtained from Rh-negative donor whose 
cells are compatible with both the infant’s and the 
mother’s serum; when possible, type O donor cells 
are usually used, but cells of the infant’s ABO type 
may be used when the mother has the same type. 
A complete cross match should be performed before 
the second or subsequent transfusion.19 In ABO in-
compatibility, O type RBCs and AB type plasma sus-
pension was preferred and most commonly used.8 
Though the incidence of hemolytic disease of the 
newborn caused by anti-D is much less in our coun-
try than in the West, the same conditions resulting 
from anti-E, anti-c, or anti-Mia are also important 
issues.8,9 Transfusion for stem cell transplantation 
candidates is also a very special and important issue, 
and the choices of blood are listed in Table 6.
3. Hemostatic transfusion therapy
The diseases commonly leading to hemorrhagic 
condition are: (1) diseases causing thrombocytope-
nia; (2) diseases due to thrombocyte dysfunction; 
(3) disorders due to coagulation factor deficiency; 
(4) disseminated intravascular coagulation (DIC); (5) 
vasculitis; (6) trauma. The characteristics of these 
diseases are so varied that their therapy should de-
pend on the specific needs associated with the un-
derlying diseases. The blood products indicated for 
certain diseases are shown in Table 2. The princi-
ple treatment modalities are discussed separately 
below.
Table 5  Choice of red cell/or cell suspension ABO type in transfusion for neonates or infants aged under 4 months
Type of neonate
 Type of First choice of Second choice of Type of plasma of
 mother RBC RBC cell suspension
A O O; PRBC   A, AB
A A A; PRBC O; PRBC A, AB
A B O; PRBC  A, AB
A AB A; PRBC/WB O; PRBC A, AB
B O O; PRBC  B, AB
B A O; PRBC  B, AB
B B B; PRBC/WB O; PRBC B, AB
B AB B; PRBC/WB O; PRBC B, AB
O O O; PRBC/WB  O, A, B, AB
O A O; PRBC/WB  O, A, B, AB
O B O; PRBC/WB  O, A, B, AB
AB A A; PRBC O; PRBC AB
AB B B; PRBC O; PRBC AB
AB AB AB; PRBC/WB A, B, O; PRBC AB
A, B, O, AB ? O; PRBC  AB
PRBC = packed RBC; WB = whole blood.
Table 6   Choice of blood in BMT or stem cell trans-
plantation
Recipient Donor Red cells
A O O
A B O
A AB A or O
B O O
B A O
B AB B or O
AB O O
AB B B or O
AB A A or O
O A O
O B O
O AB O
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3.1. Thrombocyte transfusion
Thrombocytopenia is the most common hematologi-
cal abnormality in critically ill patients with various 
underlying diseases (e.g., malignancies, idiopathic 
thrombocytopenic purpura, aplastic anemia, DIC) 
and in patients in the neonatal ICU (NICU). Roughly 
one quarter of all NICU patients and half of all sick 
preterm neonates and most hematology/oncology 
patients and septic patients develop thrombocy-
topenia.21−26 In neonates, early-onset thrombocy-
topenia (< 72 hours) is most commonly associated 
with fetomaternal conditions complicated by pla-
cental insufficiency and/or hypoxia. The resulting 
neonatal thrombocytopenia is usually mild to mod-
erate, may resolve spontaneously, and requires no 
specific therapy. Deviation from this pattern of 
thrombocytopenia suggests the presence of more 
significant precipitating conditions. The most impor-
tant of these are immune thrombocytopenia, and 
every NICU should develop investigation and treat-
ment protocols to manage these cases promptly 
and avoid unnecessary risk of hemorrhage. In con-
trast, late-onset thrombocytopenia (> 72 hours) is 
almost always associated with sepsis or necrotizing 
enterocolitis, and the associated thrombocytopenia 
is severe, prolonged and often requires treatment 
with platelet transfusion.13,21
The products of platelet concentrates include 
random donor platelet concentrates, single-donor 
platelet concentrates, human leukocyte antigen-
matched single-donor platelet concentrates, and 
leukoreduced or post-irradiated platelets; all are 
processed by different procedures and have their 
different characteristics and indications. In general, 
there is no need for platelet transfusion when a 
patient’s platelet count is higher than 10,000/mm3 
and there is no active bleeding, platelet functional 
deficiency or other risk factors such as sepsis.13 
There are many conditions under which the trans-
fusion threshold of platelet transfusion should be 
raised. Generally, the factors of platelet count, func-
tion, clinical condition and age should be taken into 
consideration in the treatment guidelines for plate-
let transfusion (Tables 7 and 8). The more critically 
ill the patient, the more platelets transfused.21−26 
The critical threshold in patients younger than 4 
months old will be higher than that in older children 
(Table 7).13,22−26 There are many conditions that need 
platelet transfusion even if the platelet count is nor-
mal (Table 8), but platelet transfusion in patients 
with qualitative deficiency will be justified only 
if significant bleeding has occurred or before an 
invasive procedure.13 To avoid alloimmunization, 
Table 7  Guidelines for platelet transfusion in children with thrombocytopenia
Platelet count 5−10 × 109/L with failure of platelet production
Platelet count < 30 × 109/L in neonate with failure of platelet production
Platelet count < 50 × 109/L in stable premature infant and associated with the following:
 − active bleeding
 − invasive procedure with failure of platelet production
Platelet count < 100 × 109/L in sick premature infant and associated with the following:
 − active bleeding
 − invasive procedure in patient with disseminated intravascular coagulation
Guidelines according to age
  Children and adolescence
    Platelets < 50 × 109/L and bleeding
    Platelets < 50 × 109/L and invasive procedure
    Platelets < 20 × 109/L and marrow failure with hemorrhagic risk factors
  Infants within first 4 months of life
    Platelets < 100 × 109/L and bleeding
    Platelets < 100 × 109/L and clinically unstable
    Platelets < 50 × 109/L and invasive procedure
    Platelets < 20 × 109/L and clinically stable
Table 8   Guidelines for platelet transfusion in patients 
with normal platelet count
Active bleeding in association with qualitative 
 platelet defect
Unexplained, excessive bleeding in patient undergoing 
 cardiopulmonary bypass
Patient undergoing extracorporeal membrane 
 oxygenation:
 − with a platelet count of < 100 × 109/L
 −  with active bleeding even though with a higher 
platelet count
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thrombocyte transfusion should not be performed in 
patients with immune-mediated thrombocytopenia 
or thrombocytopenia due to acceleration of plate-
let destruction unless one of the following con-
ditions are present: (1) active bleeding state or 
life-threatening hemorrhage; (2) plan to perform an 
invasive procedure.5
3.2.  Hemostatic therapy due to coagulation 
factor deficiency or DIC
There are many clinical states resulting from con-
genital or acquired disorders that can cause critical 
bleeding events due to impairment of coagulation 
activity or thromboembolic events due to hemostatic 
unbalance. The most common disorders encountered 
are sepsis, malignancies, congenital or acquired co-
agulopathies, huge-amount stored blood transfusion 
and BET.13
Plasma-derived products such as fresh frozen 
plasma (FFP; which contains almost 80% of the orig-
inal level of all coagulation factors), cryoprecipi-
tates (rich in fibrinogen and factors VIII and XIII), 
factor concentrates, and recombinant factors are 
commonly used for the hemorrhagic diseases due 
to coagulation deficiency, depending on the char-
acteristics of the diseases. FFP is only transfused to 
replace the deficiency of plasma hemostatic pro-
teins when purified or recombinant factor concen-
trates are not available. In selected situations, FFP 
may be appropriate to use in the replacement ther-
apy of patients with antithrombin III, protein C, or 
protein S deficiency.1,13 To avoid viral transmission, 
vapor-heated or pasteurized products and genetic 
recombinant products are recommended. The most 
effective way to correct DIC is to treat the under-
lying disease. Heparin is the most common agent 
used in the anticoagulation therapy of patients with 
DIC, but the results reported were usually not sat-
isfactory. Currently, antithrombin III, protein C, or 
recombinant thrombomodulin have been suggested 
and used successfully to treat this condition.27
4. Granulocyte transfusion
Although granulocyte transfusion has been used spar-
ingly, the ability to collect markedly higher amounts 
of neutrophils from the donor mobilized by G-CSF 
has led to renewed interest, particularly for mar-
row or peripheral progenitor cell transplantation. 
Granulocyte transfusion should be reconsidered in 
neutropenic patients who continue to deteriorate 
during progressive bacterial and fungal infections 
in spite of optimal antibiotics and recombinant 
G-CSF usage. Under the following conditions, granu-
locyte transfusion may be indicated: (A) children 
and adolescents with neutrophil count < 0.5 × 109/L 
or qualitative defect whose bacterial and/or fungal 
infection is unresponsive to appropriate antimicro-
bial therapy; (B) infants within the first week of life 
with neutrophils < 3 × 109/L or thereafter with neu-
trophils < 1 × 109/L who suffer from fulminant bac-
terial infection; (C) infected patients with sustained 
bone marrow failure unresponsive to appropriate 
antimicrobial therapy.13,28,29 Because of the risk of 
GVHD, CMV infection and inducing alloimmuniza-
tion, granulocyte transfusion is recommended only 
when infection is clearly unresponsive to appropri-
ate antimicrobial therapy including antimicrobial 
drugs, intravenous immunoglobulin and recombinant 
G-CSF.13,28,29
5.  Complications of blood transfusion 
and their prevention
The major complications of transfusion are trans-
mitted infectious diseases (e.g., viral, bacterial, spi-
rochetes and parasitic), febrile and allergic transfusion 
reaction and GVHD. Hepatitis B, hepatitis C, HIV, par-
vovirus B19 and CMV are the most common diseases 
transmitted by plasma or blood products, especially 
the plasma-derived factor concentrates.1,2,5,30−33 
These complications occur very commonly in immu-
nocompromised patients after transfusion therapy 
and cause high morbidity and mortality.1,30−33 To avoid 
viral transmission, vapor-heated or pasteurized prod-
ucts and genetic recombinant products are recom-
mended.1 CMV-seronegative bloods, leukoreduced 
and/or irradiated blood are recommended for the 
prevention of CMV infection, GVHD and alloimmu-
nization in transfusion in neonates and immuno-
compromised patients (Table 9).1,20 If the clinical 
manifestations resulting from alloimmunization fre-
quently occur, washed blood products with the al-
lergens removed should be prescribed. There is no 
reason to prescribe a plasma product to a patient 
Table 9   Patients requiring irradiated blood 
components
Intrauterine transfusion
Premature infants weighing < 1200 g at birth
Patients with known or suspected cellular immune 
 deficiencies
Patients undergoing marrow or peripheral blood 
 progenitor cell transplant
Patients immunosuppressed by chemotherapy or 
 irradiation treatment
Recipients of components from blood relative
Recipients of human leukocyte antigen-matched or 
 platelet cross match-compatible components
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for nutritional supplementation because of the risk 
of complications.
6. Conclusion
Transfusion is an important but dangerous procedure 
in therapeutic practice. The characteristics of the 
disease and which components will be restored should 
be clearly recognized by the physician before trans-
fusion. It is very difficult to establish a universal 
guideline for transfusion for critically ill children, 
especially preterm neonates. The decisions made in 
transfusion practice usually depend on the patient’s 
clinical condition and the physician’s skillful judg-
ment. The issues to be considered in children are 
quite different from those in adults. Treating un-
derlying disease and targeted replacement therapy 
are the most effective approaches. The principle: 
“Complications of transfusion must be avoided, 
the rate of blood exposure should be reduced and 
the safety of the transfused agents or components 
should be maintained” must always be kept in mind 
before doing this therapy.
References
1. Chang TT. Blood component therapy in pediatrics. Acta 
Paed Sin (Suppl A) 1995;36:30−41.
2. Desmet L, Lacroix J. Transfusion in pediatrics. Crit Care 
Clin 2004;20:229−311.
3. Nahum E, Ben-Ari J, Schonfeld. Blood transfusion policy 
among European pediatric intensive care physicians. Intensive 
Care Med 2004;19:38−43.
4. Dani C, Pezzati M, Matelli E, Prussi C, Bertini G, Rubaltelli 
FF. Effect of blood transfusion on cerebral haemodynamic 
in preterm infants. Acta Paediatr 2002;91:938−41.
5. Sloan SR, Benjamin RJ, Friedman DF, Webb IJ, Silberstein L. 
Transfusion medicine. In: Nathan & Oski’s Textbook of 
Hematology of Infancy and Childhood, 6th ed. Philadelphia: 
Saunders, 2003:1709−56.
6. Jacobs BR, Lyons K, Brilli RJ. Erythropoietin therapy in 
children with bronchiolitis and anemia. Pediatr Crit Care 
Med 2003;4:123−4.
7. Laverdiere C, Gauvin F, Hebert PC, et al. Canadian Critical 
Care Trials Group. Survey on transfusion practices of pedi-
atric intensivists. Pediatr Crit Care Med 2002;3:335−40.
8. Sun CF, ed. Transfusion Medicine, 1st ed. Taipei: Landes 
Bioscience, 2003. Chapter 4: Rh type, p. 43−58; Chapter 12: 
Blood components, p. 161−216; Chapter 20: Hemolytic dis-
ease of newborn, p. 257−72.
9. Broadberry RE, Lin M. The distribution of the MiIII(GP.Mur) 
phenotype among the population of Taiwan. Transfusion Med 
1996;6:145−8.
10. Obladen M, Sachsenweger M, Stahnke M. Blood sampling in 
very low birth-weight infants receiving different levels of 
intensive care. Eur J Pediatr 1988;147:399−404.
11. Madsen LP, Rasmussen MK, Bjerregaard LL, Nohr SB, Ebbesen 
F. Impact of blood sampling in very preterm infants. Scand 
J Clin Lab Invest 2000;60:125−32.
12. Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, 
Pollack MM. Erythropoietin response to critical illness. Crit 
Care Med 1994;22:821−6.
13. Strauss RG. Blood and blood component transfusions. In: 
Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Text-
book of Pediatrics, 16th ed, Section 6, Chapters 476−480. 
Philadelphia: WB Saunders, 2000:1499−503.
14. Ringer SA, Richardson DK, Sacher RA, Keszler M, Churchill 
WH. Variations in transfusion practice in neonatal intensive 
care. Pediatrics 1998;101:194−200.
15. Lacroix J, Nadeau D, Laberge S, Gauthier M, Lapierre G, 
Farrell CA. Frequency of upper gastrointestinal bleeding in a 
pediatric intensive care unit. Crit Care Med 1992;20:35−42.
16. McGrady GA, Rettig PJ, Istre GR, Jason JM, Holmann RC, 
Evatt BL. An outbreak of necrotizing enterocolitis associa-
tion with transfusions of packed red cells. Am J Epidemiol 
1987;126:1165−72.
17. Donowitz LG, Turner RB, Searcy MAM, Luban NLC, Hendley OH. 
The high rate of blood exposure for critically ill neonates. 
Hosp Epidemiol 1989;10:509−10.
18. Bifano EM, Curran TR. Minimizing donor blood exposure in 
the neonatal intensive care unit. Perinatal Hematol 1995;
22:657−69.
19. Stoll BJ, Kliegman RM. Hemolytic disease of newborns. In: 
Behrman RE, Kliegman RM, Jenson HB eds. Nelson Textbook 
of Pediatrics, 16th ed, Chapter 99. Philadelphia: WB Saunders, 
2000:521−5.
20. Fergusson D, Hébert PC, Lee SK, et al. Clinical outcomes 
following institution of universal leukoreduction of blood 
transfusion for premature infants. JAMA 2003;16:1993−5.
21. Murray NA. Evaluation and treatment of thrombocytopenia 
in the neonatal intensive care unit. Acta Paediatr 2002;
438(Suppl):74−81.
22. Chevuru SC, Sola MC, Theriaque DW, et al. Florida Collaborative 
Neonatology Research Group. Multicenter analysis of plate-
let transfusion usage among neonates on extracorporeal 
membrane oxygenation. Pediatrics 2002;109:e89.
23. Kahn DJ, Richardson DK, Billett HH. Inter-NICU variation in 
rates and management of thrombocytopenia among very 
low birthweight infants. J Perinatol 2003;23:312−6.
24. Garcia MG, Duenas E, Sola MC, Hutson AD, Theriaque D, 
Christensen RD. Epidemiology and outcome studies of patients 
who received platelet transfusions in the neonatal intensive 
care unit. Perinatol 2001;21:415−20.
25. Del Vecchio A, Sola MC, Theriaque D, et al. Platelet trans-
fusions in the neonatal intensive care unit: factors predicting 
which patients will require multiple transfusion. Transfusion 
2001;41:803−8.
26. Robert IA, Murray NA. Neonatal thrombocytopenia: new 
insights into pathogenesis and implications for clinical man-
agement. Curr Opin Pediatr 2001;13:16−21.
27. Maruyama I. Recombinant thrombomodulin and activated 
protein C in the treatment of disseminated intravascular 
coagulation. Thromb Haemost 1999;82:718−21.
28. Strauss RG. Therapeutic granulocyte transfusions in 1993. 
Blood 1993;81:1675.
29. Strauss RG. Granulocytes transfusions. In: Rossi EC, Simon TL, 
Moss GS, eds. Principle of Transfusion Medicine, 2nd ed. 
Baltimore: Williams & Wilkins, 1996:321.
30. Griffin MP, O’Shea M, Brazy JE, Klein D, Koepke J, Wilfert 
CM. Cytomegalovirus infection in a intensive care unit: 
subsequent morbidity and mortality of seropositive infants. 
J Perinatol 1990;10:43−5.
31. Weston PJ, Farmer K, Groxson MC, Ramirez AM. Morbidity 
from acquired cytomegalovirus infection in a neonatal inten-
sive care unit. Aust Paediatr J 1989;25:138−42.
32. Hubert C, Janot C, George JC, van Melkebecke E, Andre M, 
Vert P. Post-transfusion cytomegalovirus infection in pre-
mature infants weighing less than 1500 g. Pediatrics 1989;
44:471−9.
33. Munoz PE, Herruzo CR, Garcia CJ, Femandez AM, Quero J. 
Nosocomial infection over three years in a neonatal intensive 
care unit: multivariate study. Med Clin (Barc) 1997;109:
527−31.
